Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Is HIV a provoking factor for venous thrombotic events?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. How do we preserve health among adults living with HIV?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Language used to convey HIV infection risk is important - Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The EuroSIDA study: 25 years of scientific achievements

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Andrew N Phillips
  • Loveleen Bansi-Matharu
  • Francois Venter
  • Diane Havlir
  • Anton Pozniak
  • Daniel R Kuritzkes
  • Annemarie Wensing
  • Jens D Lundgren
  • Deenan Pillay
  • John Mellors
  • Valentina Cambiano
  • Andreas Jahn
  • Tsitsi Apollo
  • Owen Mugurungi
  • David Ripin
  • Juliana Da Silva
  • Elliot Raizes
  • Nathan Ford
  • George K Siberry
  • Ravindra K Gupta
  • Ruanne Barnabas
  • Paul Revill
  • Jennifer Cohn
  • Alexandra Calmy
  • Silvia Bertagnolio
View graph of relations

BACKGROUND: The integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerability and a lower risk of resistance emergence. WHO requested updated modelling results for its 2019 Antiretroviral Guidelines update, which was restricted to the choice of dolutegravir or efavirenz in new ART initiators. In response to this request, we modelled the risks and benefits of alternative policies for initial first-line ART regimens.

METHODS: We updated an existing individual-based model of HIV transmission and progression in adults to consider information on the risk of neural tube defects in women taking dolutegravir at time of conception, as well as the effects of dolutegravir on weight gain. The model accounted for drug resistance in determining viral suppression, with consequences for clinical outcomes and mother-to-child transmission. We sampled distributions of parameters to create various epidemic setting scenarios, which reflected the diversity of epidemic and programmatic situations in sub-Saharan Africa. For each setting scenario, we considered the situation in 2018 and compared ART initiation policies of an efavirenz-based regimen in women intending pregnancy, and a dolutegravir-based regimen in others, and a dolutegravir-based regimen, including in women intending pregnancy. We considered predicted outcomes over a 20-year period from 2019 to 2039, used a 3% discount rate, and a cost-effectiveness threshold of US$500 per disability-adjusted life-year (DALY) averted.

FINDINGS: Considering updated information on risks and benefits, a policy of ART initiation with a dolutegravir-based regimen rather than an efavirenz-based regimen, including in women intending pregnancy, is predicted to bring population health benefits (10 990 DALYs averted per year) and to be cost-saving (by $2·9 million per year), leading to a reduction in the overall population burden of disease of 16 735 net DALYs per year for a country with an adult population size of 10 million. The policy involving ART initiation with a dolutegravir-based regimen in women intending pregnancy was cost-effective in 87% of our setting scenarios and this finding was robust in various sensitivity analyses, including around the potential negative effects of weight gain.

INTERPRETATION: In the context of a range of modelled setting scenarios in sub-Saharan Africa, we found that a policy of ART initiation with a dolutegravir-based regimen, including in women intending pregnancy, was predicted to bring population health benefits and be cost-effective, supporting WHO's strong recommendation for dolutegravir as a preferred drug for ART initiators.

FUNDING: Bill & Melinda Gates Foundation.

Original languageEnglish
JournalThe Lancet HIV
Volume7
Issue number3
Pages (from-to)e193-e200
ISSN2352-3018
DOIs
Publication statusPublished - Mar 2020

ID: 59339634